“Maybe that’s a good thing to have a virus that is more infectious but less deadly,” Tambyah told Reuters.
Tambyah said most viruses tend to become less virulent as they mutate.
“It is in the virus’ interest to infect more people but not to kill them because a virus depends on the host for food and for shelter,” he said.
Phase 1 and 2 human clinical trials of two of the vaccine candidates, developed indigenously by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR), and Zydus Cadila Ltd, are currently underway.
The Serum Institute of India has been permitted to conduct Phase 2 and 3 human clinical trials of the third vaccine candidate developed by Oxford University. The Pune-based institute has partnered with AstraZeneca for manufacturing the vaccine.
With the FDA’s emergency use authorisation, the testing method is immediately available to other diagnostic laboratories that want to start using the new test, which can be scaled up quickly for use across the nation and, perhaps, beyond in the coming weeks, researchers said
”This is a huge step forward to make testing more accessible,” said Chantal Vogels, a Yale postdoctoral fellow, who led the laboratory development and validation along with Doug Brackney, an adjunct assistant clinical professor.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.